21.50k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change Today||1 Month Return||1 Year Return||Total Return|
|The Fight Against COVID19||+5.21%||-||-||-|
|Symbol||Company Name||Last Price||Change||% Change||Market Time||Volume||Avg Vol (3 month)||Market Cap|
|JNJ||Johnson & Johnson||172.18||-0.48||-0.28%||4:00 p.m. EDT||5.75M||6.67M||453.42B|
|PFE||Pfizer Inc.||43.45||+1.35||+3.21%||4:02 p.m. EDT||52.82M||25.34M||243.22B|
|ABBV||AbbVie Inc.||118.55||+0.59||+0.50%||4:02 p.m. EDT||5.55M||6.37M||209.39B|
|MRNA||Moderna, Inc.||349.32||+20.82||+6.34%||4:00 p.m. EDT||12.95M||12.87M||140.26B|
|SNY||Sanofi||52.06||+0.46||+0.89%||4:00 p.m. EDT||1.55M||1.34M||130.41B|
|GSK||GlaxoSmithKline plc||39.5||-0.02||-0.05%||4:00 p.m. EDT||4.44M||4.27M||99.38B|
|GILD||Gilead Sciences, Inc.||70.06||+1.13||+1.64%||4:00 p.m. EDT||7.10M||6.76M||87.87B|
|BNTX||BioNTech SE||313.45||+29.45||+10.37%||4:00 p.m. EDT||4.88M||3.20M||75.70B|
|REGN||Regeneron Pharmaceuticals, Inc.||586.41||+5.40||+0.93%||4:00 p.m. EDT||404.04k||755.01k||62.48B|
|TAK||Takeda Pharmaceutical Company Limited||17.13||+0.36||+2.15%||4:00 p.m. EDT||2.45M||2.02M||54.01B|
|NVAX||Novavax, Inc.||189.01||+10.00||+5.59%||4:00 p.m. EDT||2.67M||4.22M||14.00B|
|VIR||Vir Biotechnology, Inc.||37.05||+0.61||+1.67%||4:00 p.m. EDT||731.40k||714.25k||4.82B|
|INO||Inovio Pharmaceuticals, Inc.||8.67||+0.41||+4.96%||4:00 p.m. EDT||3.21M||5.45M||1.82B|
Pfizer CEO is no stranger to risks, and hopes to repeat the company's COVID-19 success with an oral treatment.
Dr. Manish Garg, Emergency Medicine Physician & Co-Founder of World Academic Council of Emergency Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment Dupixent helped it beat second-quarter results expectations. Sanofi, which shocked investors last year with a delay to a COVID-19 vaccine it is developing with Britain's GlaxoSmithKline, reiterated its confidence in the shot, which it hopes will secure regulatory approval by the end of the year. Overall, Sanofi's sales rose 12.4% in the second quarter to 8.74 billion euros, while business net income - a figure the company uses as its core metric to measure profits - was up 16.8% to 1.73 million euros.